Phase I/II study of Cetuximab combined with S-1 and irrinotecan (CeIRIS) in KRAS wild type metastatic colorectal cancer patients refractory to treatment with oxaliplatin and fluoropyrimidine. - KMOG0901 CeIRIS trial

Kyushu Medical Oncology Group0 个研究点目标入组 40 人开始时间: 2010年3月4日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Severe comorbidity (active infectious disease, severe cerebrovascular disorder, uncontrolable diabetes, heart failure, angina, myocardial infarction within three months, severe hepatic disorder, jaundice etc) 2) Comorbidity or history of interstitial lung disease or pulmonary fibrosis 3) Massive pleural effusion or ascites 4) Symptomatic brain metastasis 5) Wattery diarrhea 6) Paralytic or mechanical bowel obstruction 7) Patients who is receiving Fluorocytosine 8) Patients who is receiving Atazanavir Sulfate 9) Simultaneous or metachronous double cancers 10) History of severe allergy 11) Current chronic daily treatment with corticosteroids(oral intake or intravenously) 12) Severe infectious disease 13) Amalgamation of mental disease or psychotic manifestation 14) Pregnant or lactating women or women of childbearing potential. 15) Any other patient whom the physician in charge of the study judges to be unsuitable.

发起方

Kyushu Medical Oncology Group